AASLD practice guidelines. Chronic hepatitis B: Current therapeutic recommendations;AASLD practice guidelines. Hepatita cronicǎ B: Actualizarea recomandǎrilor terapeutice

Romanian Journal of Gastroenterology

Volumn 13, Issue 2, 2004, Pages 150-154

  Lok, Anna S F ^a   McMahon, Brian J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; LAMIVUDINE;

CHRONIC HEPATITIS; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PRACTICE GUIDELINE; REVIEW; SEROCONVERSION; VIRUS RESISTANCE;

HEPATITIS B, CHRONIC; HUMANS;

EID: 3142516286     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Lok ASF, McMahon BJ. AASLD Practice Guidelines: chronic hepatitis B. Hepatology 2001; 34: 1225-1241
2. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al., for the International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N. Eng J Med 2002; 346; 1706-1713
3. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-755.
4. Lee KM, Cho SW, Kim SW, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine - induced HBeAg seroconversion. J Viral Hepat 2002; 9: 208-212
5. van Nunem AM, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424
6. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5-years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001; 16 (suppl 1): A60 (abstract)
7. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003: 124: 105-117
8. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. To continue or not to continue lamivudine therapy after emergence of YMDD mutations. Gastroenterology 2002; 122: A628 (abstract)
9. Wong VW, Chan HL, Wong ML, Leung N. Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B? J Hepatol 2002; 36 (suppl 1): 177 (abstract)
10. Marcellin p, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen - positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816
11. Hadziyannis SJ, Tassopoulus NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen - negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807
12. Hadziyannis S, Tassopoulus N, Heathcote J et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B. J Hepatol 2003; 38 (suppl 2): 143 (abstract)
13. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine - resistant hepatitis B in pre- and post - liver transplantation patients. Hepatology 2003; 38: 1419-1427
14. Peters MG, Hann HW, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine - resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101
15. Chang TT, Lim SG, Hadziyannis S et al. Long-term safety of adefovir dipivoxil (ADV) 10 mg once daily for chronic hepatitis B (CHB): an integrated analysis of two phase III studies. J Hepatol 2003; 38 (suppl 2): 133 (abstract)
16. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297
17. Lau GKK, He ML, Fong DYT et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-709
18. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58-62
19. Chan TM, Fang GX, Tang CSO, Cheng IKP, Lai KN, Ho SKN. Preemptive lamivudine therapy based on HBV DNA level in HBsAg - positive kidney allograft recipients. Hepatology 2002; 36: 1246-1252.